There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on VistaGen Therapeutics (VTGN – Research Report) and Acrivon Therapeutics, Inc. (ACRV – Research Report) with bullish sentiments.
VistaGen Therapeutics (VTGN)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics, with a price target of $12.00. The company’s shares closed last Friday at $4.75, close to its 52-week low of $1.62.
According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VistaGen Therapeutics with a $12.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Acrivon Therapeutics, Inc. (ACRV)
Maxim Group analyst Michael Okunewitch reiterated a Buy rating on Acrivon Therapeutics, Inc. yesterday and set a price target of $24.00. The company’s shares closed last Friday at $8.46.
According to TipRanks.com, Okunewitch is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Acrivon Therapeutics, Inc. is a Strong Buy with an average price target of $21.63, which is a 153.6% upside from current levels. In a report issued on April 25, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VTGN:
